硝苯啶对大鼠肝纤维化肝透明质酸、羟脯氨酸及氨基葡萄糖苷酶的影响  

Effects of Nifedipine on Hepatic Hyaluronic Acid,Hydroxyproline and Glucosaminidase Contents in Rats with Liver Fibrosis

作　　者：车建途[1] 陆汉明[1] 李定国[1] 王秀玲[1] 陈强[1] 

机构地区：[1]上海第二医科大学新华医院,中国医学科学院药物研究所

出　　处：《中国医学科学院学报》1994年第1期35-38,共4页Acta Academiae Medicinae Sinicae

摘　　要：用四氯化碳（ＣＣｌ_４）造成大鼠肝纤维化，发现钙拮抗剂硝苯啶（Ｎｉｆ）明显降低早期治疗组大鼠肝纤维化肝透明质酸（ＨＡ）、羟脯氨酸（Ｈｙｐ）含量及大剂量组肝Ｎ－乙酰－β－氨基葡萄糖苷酶（β－ＮＡＧ）活性。晚期治疗组中，ＨＡ含量及大剂量组β－ＮＡＧ，活性仍明显降低。Ｎｉｆ对大鼠肝纤维化肝ＨＡ、Ｈｙｐ和β－ＮＡＧ的影响与其剂量有一定依赖关系。实验提示Ｎｉｆ对ＣＣｌ_４诱导的大鼠肝纤维化有抑制，甚至可能有一定逆转作用。In early stage treatment groups,Nifedipine(Nif)could significantly reduce hepatic hyaluroic acid(HA)and hydroxyproline(Hyp)contents in rats in which liver fibrosis had been induced by CCl4 treatment.N-acetyl-β-glucosaminidase(β-NAG)activity showed a similar change in the high dosage group. In late stage treatment groups,HA was reduced markedly,and decreased β-NAG lvels were noted in the high dosage group.These effects on HA,Hyp and β-NAG were dependent on Nif dosage. The results suggest that Nif could inhibit the development of liver fibrosis in rats,and may even reverse it.

关 键 词：钙拮抗剂 硝苯啶 羟脯氨酸 肝硬变 

分 类 号：R965.2[医药卫生—药理学]